Paratek Pharmaceuticals Inc.

NASDAQ:PRTK   3:59:59 PM EDT
10.22
-0.21 (-2.01%)
Earnings Announcements

Paratek Pharmaceuticals - Q1 Revenue Rose 107% To $16.4 Mln

Published: 05/17/2021 11:48 GMT
Paratek Pharmaceuticals Inc. (PRTK) - Q1 Revenue Estimate $28.7 Million -- Refinitiv Ibes Data (analyst estimates).
Qtrly Loss per Share $0.39.
Barda Has Initiated First Procurement of Nuzyra Valued at About $38 Million in Q2 of 2021.
Nuzyra Expansion Into Primary Care Setting Underway.
Revenue is expected to be $61 Million
Adjusted EPS is expected to be $0.23

Next Quarter Revenue Guidance is expected to be $27.43 Million
Next Quarter EPS Guidance is expected to be -$0.29

More details on our Analysts Page.